Skip to content
Evofem Biosciences, Inc.
About Us
Mission
Management
Board of Directors
Saundra Pelletier
GILLIAN GREER, CBE, Ph.D.
KIM P. KAMDAR, Ph.D.
Tony O’Brien
Lisa Rarick, MD, FACOG
Colin Rutherford
Our Product
phexxi
®
Pipeline
In Development
Posters & Publications
Investors
Investor Overview
Events & Presentations
Press Releases
Stock Information
Financial Information
SEC Filings
Analyst Coverage
Corporate Governance
Committee Composition
Board of Directors
Charters + Code of Ethics
Investor Resources
Investor Contact
Investor FAQs
Contact
Investor Contact
Media Contact
General Contact
Careers
Pregnancy Intendedness with Vaginal PH Modulator: Results from the Phase 3 Ampower Trial
Post navigation
Previous:
Compliance with Vaginal PH Modulator in the Phase 3 Ampower Contraceptive Trial
Next:
EVO100 Prevents Chlamydia and Gonorrhea in Women at High-Risk for Infection
Back
to
Top
